Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 May 2005

Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Inganäs M, Carlsson G, Ohd J, Rudenstam C-M, Gustavsson B, Bergh J

Abstract excerpt

BACKGROUND: TP53 has been described as a prognostic factor in many malignancies, including breast cancer. Whether it also might be a predictive factor with reference to chemo- and endocrine therapy is more controversial. PATIENTS AND METHODS: We investigated relapse-free (RFS), breast cancer-corrected (BCCS) and overall survival (OS) related to TP53 status in node-positive breast cancer patients that had received...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cisplatin

Share to Fluorouracil

Share to Methotrexate

Share to Neoplasms, Hormone-Dependent

Share to Probability

Share to Tamoxifen

Source

Identifiers

PMID: 15802278
DOI: 10.1093/annonc/mdi150

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.PMID 15802278Read ↗

TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients.Semantic proximity Read ↗

TP53 mutations predict poor breast cancer-specific survival in ER-positive breast cancer patients.Semantic proximity Read ↗

Prognostic value of p53 molecular status in high-risk primary breast cancer.Semantic proximity Read ↗

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.Semantic proximity Read ↗

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.Semantic proximity Read ↗

TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.Semantic proximity Read ↗

Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients.Semantic proximity Read ↗

A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients.Semantic proximity Read ↗

Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis.Semantic proximity Read ↗

Only Missense Mutations Affecting the DNA Binding Domain of P53 Influence Outcomes in Patients with Breast CarcinomaSemantic proximity Read ↗

p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings.Semantic proximity Read ↗

Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.